Drugs / human single chain IL-12 mRNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05392699 | May 2022 → Mar 2025 overdue | — | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human single chain IL-12 mRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05392699 ↗ |
| Known as | ABOD2011 | “This product (ABOD2011) is a new generation mRNA product for intratumoral injection.” NCT05392699 ↗ |
| Modality | Messenger RNA (mRNA) | “This product (ABOD2011) is a new generation mRNA product for intratumoral injection.” NCT05392699 ↗ |